

This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu).


THE ROLE OF NEUROFIBROMIN IN REGULATION OF ENDOTHELIAL CELL
AND VASCULAR SMOOTH MUSCLE CELL FUNCTIONS IN RESPONSE TO
NEUROFIBROMA DERIVED GROWTH FACTORS

Amy M. Munchhof


Submitted to the faculty of the University Graduate School
in partial fulfillment of the requirements
for the degree
Doctor of Philosophy
in the Department of Biochemistry and Molecular Biology
Indiana University

July 2008

Accepted by the Faculty of Indiana University, in partial fulfillment of the requirements for the degree of Doctor of Philosophy.




David A. Ingram, MD, Chair




Peter Roach, PhD

Doctoral Committee



Lawrence Quilliam, PhD

Date of Oral Examination
January 19, 2007



D. Wade Clapp, MD

ABSTRACT

Amy M. Munchhof

THE ROLE OF NEUROFIBROMIN IN REGULATION OF ENDOTHELIAL CELL AND VASCULAR SMOOTH MUSCLE CELL FUNCTIONS IN RESPONSE TO NEUROFIBROMA DERIVED GROWTH FACTORS

Neurofibromatosis Type I (NF1) is a common autosomal dominant genetic disorder caused by mutations in the *NF1* tumor suppressor gene that encodes for neurofibromin, a GTPase activating protein (GAP) that negatively regulates Ras activity. Ras signaling pathways regulate many different cellular processes and Ras is activated in many cancers. NF1 patients develop multiple cutaneous benign neurofibromas that are highly vascular, plexiform neurofibromas, cardiovascular disease, vascular occlusive disease, and malignant myeloid disease in childhood. Endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) are essential components of vessels. Recent studies suggest that *Nf1*^{+/-} mice have increased angiogenesis *in vivo* and demonstrate Ras signaling in VSMCs is important in the pathogenesis of arterial occlusive disease. However, the function of neurofibromin in human ECs and VSMCs and the biochemical mechanism by which neurofibromin regulates neoangiogenesis are not known. In addition how Ras signals are terminated in these cells is essentially unknown. In our work here utilizing *Nf1*^{+/-} mice, endothelial progenitor cells derived from NF1 patients, VSMCs harvested from *Nf1*^{+/-} mice, and shRNA targeted to *NF1* to silence neurofibromin deficient ECs and VSMCs have increased proliferation and migration *in vitro* in response to neurofibroma derived growth factors via a discrete Ras effector pathway, the Ras-Mek-Erk pathway. In addition, we demonstrate *Nf1*^{+/-} mice have increased angiogenesis

in vivo in response to neurofibroma derived growth factors via the Ras-Mek-Erk pathway. Furthermore, utilizing shRNA to silence expression of p12-GAP, the other mammalian RasGAP, we show p120GAP deficient primary human ECs have decreased migration in response to neurofibroma derived growth factors. These studies suggest p120GAP and neurofibromin have distinct functions in ECs. Collectively these studies demonstrate neurofibromin functions as a GAP for Ras in vascular cells and identify a unique pathway in *Nf1*^{+/-} ECs as a potential therapeutic target in the neurofibroma microenvironment. Also, they identify neurofibromin as a novel regulator of Ras activity in VSMCs which provides a framework for understanding cardiovascular disease in NF1 patients and a mechanism by which Ras signals are attenuated for maintaining VSMC homeostasis in blood vessel walls.

TABLE OF CONTENTS

LIST OF FIGURES.....	xii
ABBREVIATIONS.....	xviii
INTRODUCTION.....	1
I. Endothelial Cells (ECs) and Angiogenesis.....	1
II. Ras Proteins.....	5
III. RasGAPs.....	9
IV. Angiogenic Growth Factors.....	12
V. Angiogenic Growth Factors and EC Functions Required for Angiogenesis.....	15
A. <i>Vascular Endothelial Growth Factor (VEGF), Basic Fibroblast Growth Factor (bFGF) and Proliferation</i>	15
B. <i>VEGF, bFGF, and Migration</i>	18
C. <i>VEGF, bFGF, and Capillary Formation</i>	21
VI. Vascular Smooth Muscle Cells (VSMCs).....	24
VII. Neurofibromatosis Type I.....	26
VIII. p120GAP (<i>Rasa 1</i>): Capillary Malformations-Arteriovenous Malformations.....	36
METHODS.....	46
I. Animals.....	46
II. Peripheral Blood Samples.....	46
III. Preparation of Mononuclear Cells (MNCs).....	47
IV. Culture of Endothelial Progenitor Cells (EPCs).....	47
V. Immunophenotyping of Endothelial Progenitor Cells (EPCs).....	48
VI. Human Microvascular Endothelial Cell (HMVEC) Culture.....	49
VII. Murine Schwann Cell Culture and Generation of Schwann Cell Conditioned Media (SCCM).....	50
VIII. Generation of siRNA and snRNA Constructs.....	50
IX. Retroviral Packaging.....	52
X. Transduction of Target Cells.....	52
XI. <i>In vivo</i> Matrigel Plug Assays.....	53
XII. Thymidine Incorporation Assays.....	53
XIII. Haptotaxis Assays.....	54
XIV. Western Blotting.....	55
XV. Ras Activation Assay.....	56
XVI. Matrigel Branching Assay.....	57
RESULTS.....	58
I. Characterization of Neurofibromin-Deficient Primary ECs.....	58
A. <i>Reduction of Neurofibromin Levels by shRNA</i>	58

	B. <i>Transduction of Human ECs with shRNA Directed Against Neurofibromin Increases Activation of the Ras-Erk Pathway</i>	59
II.	Functional Analysis of Neurofibromin-Deficient Human Microvascular ECs.....	60
	A. <i>Neurofibromin-Deficient Human ECs have Increased Proliferation and Migration</i>	60
	B. <i>Increased Proliferation and Migration of Neurofibromin-Deficient Human ECs is Mediated Through Erk Activation</i>	64
III.	Characterization of ECs Isolated from NF1 Patients.....	64
	A. <i>Isolation of ECs from NF1 Patients</i>	64
	B. <i>ECs Isolated from NF1 Patients have Increased Proliferation Migration, and Erk Activation in Response to VEGF and bFGF</i> ...	69
	C. <i>Increased Proliferation and Migration of ECs Isolated from NF1 Patients is Mediated Through Erk Activation</i>	72
IV.	Analysis of Angiogenesis in vivo in <i>Nf1</i> Heterozygous Mice.....	72
	A. <i>Nf1</i> ^{+/-} mice have an Increased Angiogenic Response to bFGF and VEGF via Hyperactivation of Erk.....	72
	B. <i>Nf1</i> ^{+/-} mice have an Increased Angiogenic Response to SCCM via Hyperactivation of Erk.....	76
V.	Characterization of <i>Nf1</i> ^{+/-} VSMCs.....	77
	A. <i>Immunohistochemical Staining of Isolated Murine VSMCs</i>	77
	B. <i>Ras and Erk Activation are Increased in <i>Nf1</i>^{+/-} VSMCs</i>	77
VI.	Functional Analysis of <i>Nf1</i> Heterozygous VSMCs.....	79
	A. <i>Nf1</i> ^{+/-} VSMCs have Increased Proliferation and Migration in Response to PDGF-BB Compared to WT Controls.....	79
	B. <i>Increased Migration and Proliferation of <i>Nf1</i>^{+/-} VSMCs is Mediated via Hyperactivation of Erk</i>	83
VII.	Characterization of Neurofibromin-Deficient Human VSMCs.....	85
	A. <i>siRNA Reduction of Neurofibromin Expression in Human VSMCs Increases Erk Activation</i>	85
	B. <i>siRNA Reduction of Neurofibromin Expression in Human VSMCs Increases their Proliferation and Migration via Hyperactivation of Erk</i>	90
VIII.	Characterization of <i>Nf1</i> ^{+/-} Fibroblast Conditioned Media (FCM).....	90
	A. <i>Nf1</i> ^{+/-} FCM is a Potent Stimulus for <i>Nf1</i> ^{+/-} VSMC Migration.....	90
	B. <i>PDGF Concentration is Increased in <i>Nf1</i>^{+/-} FCM Compared to WT CM</i>	94

DISCUSSION.....	104
I. Neurofibromin Functions as a GAP for Ras in Human ECs.....	104
II. Proliferation and Migration of Neurofibromin-Deficient Human Micro-Vascular ECs in Response to VEGF and bFGF is Mediated via Hyperactivation of the Ras-Erk Pathway.....	108
III. NF1 Patient Derived ECs have Increased Proliferation and Migration via Hyperactivation of Erk.....	111
IV. Angiogenesis is Increased <i>in vivo</i> in <i>Nf1</i> ^{+/-} Mice in Response to VEGF, bFGF, and <i>Nf1</i> ^{-/-} SCCM.....	112
V. Neurofibromin Functions as a GAP for Ras in VSMCs.....	114
VI. Proliferation and Migration of Neurofibromin-Deficient Human and Murine VSMCs in Response to PDGF-BB is Mediated via Hyper-Activation of the Ras-Erk Pathway.....	115
VII. <i>Nf1</i> Heterozygous FCM Stimulates <i>Nf1</i> ^{+/-} VSMC Migration via the PDGF-Ras-Erk Pathway.....	118
VIII. Neurofibromin-Deficient VSMCs and Vasculopathies.....	118
IX. Neurofibromin-Deficient VSMCs and Neurofibromas.....	120
SUMMARY AND FUTURE DIRECTIONS.....	124
I. Neurofibromin.....	124
II. p120GAP.....	129
REFERENCES.....	144
Curriculum Vitae.....	